That framing is right for this community. The realistic aim is informed risk, not zero risk - zero risk is unavailable here. Knowing what you are actually managing and doing it actively is what makes the difference.
SHOTZY handles variable schedules well - if injection day shifts for travel or a busy week, the custom interval tracking stays accurate. Worth running in the background regardless.
A year on Mounjaro with T2D labs improving is the milestone that closes the 'just eat less' argument - the metabolic shift is hard to fake in bloodwork.
A year on Mounjaro with the diabetes numbers turning is the outcome it was designed for. Month 3 leveling out is common; the year view is what the entire early phase was working toward.
From 270 down to 175 now. Month on Wegovy pills first, then switched to tirzepatide a few weeks back. Dropped 10 already and the non-scale stuff feels amazing.
Historically interesting. Forty years back you could get stuff basically like amphetamines at truck stops. Then they got hard to get cause some converts to meth. Chemically between Adderall and meth is not that different. Closer to meth, more of that good stimulant feel. From a pure chemistry angle wild. Odd to think how much Adderall gets given to kids. Sure studies hard on that, not judging those who truly need it. But maybe eighty percent of folks in grad school were snorting it during tests.
The wonder-drug framing creates a gap between expectation and reality that makes slow responders feel like they're doing something wrong - posting the realistic version of the journey is genuinely useful for people early in the process who are second-guessing results that are actually fine.
the A1C from 6.5 to 4.9 is a clinically meaningful result that goes beyond what most people expect from GLP-1 therapy - moving below the 5.7 prediabetes cutoff from a confirmed diabetes-range A1C represents a metabolic state shift, not just improvement. the retinal check recommendation for GLP-1 users with diabetes history is also the right standard of care; rapid glycemic improvement can temporarily stress retinal vasculature and the floater timing makes that check worth prioritizing
1700-2000 calories for 7 months at a steady rate is disciplined. The hesitation about moving to 12.5 when everything is working at the current dose is a reasonable one - if the A1C and weight are both moving in the right direction, the case for going higher is less urgent than it would be for someone who plateaued. What specifically is the glucose concern driving the hesitation?
A1C below pre-diabetic level is the metabolic win that makes Mounjaro different from a weight loss intervention framing. Catching T2D early and getting that kind of response in one year is the best-case timeline. Your friend's insulin dependency converting is the version of the same story at a more advanced stage - does the doc have a view on how long yours might need to continue?
Switching from Zepbound to Mounjaro when insurance changed, and Mounjaro covered through the T2D diagnosis, is the path that works out when the underlying condition justifies the prescription. The OP at one year in with the A1C result is what staying on it through the coverage hoops looks like. How is the A1C tracking since the insurance switch and brand change?
5 weeks and already seeing the mood improvement alongside the facial flushing, feeling cold a lot - the early mixed bag where some effects show up fast and others take months. switching from Ozempic to this at the dr's recommendation for T2D is probably gonna look a lot different at 12 months than it does right now. the OP at a full year with the A1C result is where you're heading. wanna hear what the cold feeling does over time - does it stick around?